CLINICAL TRIALS PROFILE FOR RYDAPT

All Clinical Trials for Rydapt

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Novartis Pharmaceuticals	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT01830361 ↗	Trial to Assess the Efficacy of Midostaurin (PKC412) in Patients With c-KIT or FLT3-ITD Mutated t(8;21) AML	Completed	Technische Universität Dresden	Phase 2	2013-03-13	To assess the efficacy of tyrosine-kinase inhibitor midostaurin in c-KIT or FLT3-ITD mutated t(8;21) AML. To assess the efficacy of midostaurin depending on the type of c-KIT mutation
NCT02115295 ↗	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Recruiting	National Cancer Institute (NCI)	Phase 2	2014-05-19	This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
NCT02115295 ↗	Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia	Recruiting	M.D. Anderson Cancer Center	Phase 2	2014-05-19	This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

Clinical Trial Conditions for Rydapt

Condition Name

Condition Name for Rydapt
Intervention	Trials
Acute Myeloid Leukemia	10
Myelodysplastic Syndrome	2
Myelodysplastic Syndrome With Excess Blasts-2	2
Untreated Adult Acute Myeloid Leukemia	2

Condition MeSH

Condition MeSH for Rydapt
Intervention	Trials
Leukemia, Myeloid, Acute	11
Leukemia, Myeloid	11
Leukemia	10
Syndrome	3

Clinical Trial Locations for Rydapt

Trials by Country

Trials by Country for Rydapt
Location	Trials
United States	82
Germany	5
Netherlands	2
Switzerland	1

Trials by US State

Trials by US State for Rydapt
Location	Trials
California	4
Florida	4
Georgia	3
Washington	3
Tennessee	3

Clinical Trial Progress for Rydapt

Clinical Trial Phase

Clinical Trial Phase for Rydapt
Clinical Trial Phase	Trials
Phase 3	1
Phase 2/Phase 3	1
Phase 2	6

Clinical Trial Status

Clinical Trial Status for Rydapt
Clinical Trial Phase	Trials
Recruiting	5
Active, not recruiting	2
Withdrawn	2

Clinical Trial Sponsors for Rydapt

Sponsor Name

Sponsor Name for Rydapt
Sponsor	Trials
Novartis Pharmaceuticals	3
National Cancer Institute (NCI)	3
Pfizer	2

Sponsor Type

Sponsor Type for Rydapt
Sponsor	Trials
Other	14
Industry	9
NIH	3